Active Recombinant Human VEGF 165a

C854H1340N274O257S22

0.343

Endotoxin Level : < 0.04 EU / ug protein (LAL method)

Vascular endothelial growth factor is a member of the platelet-derived growth factor family. It is a specific mitogen for vascular endothelial cells in vitro and a strong angiogenic factor in vivo. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. In addition to its action as a mitogen it is a potent vascular permeability factor (VPF) in vivo and is also a chemo attractant for monocytes cells. VEGF binds to the FLT1/VEGFR1 and KDR/VEGFR2 present on endothelial cells. Substantial evidence implicates VEGF in the induction of tumour metastasis by stimulating the production of matrix metalloproteinase (MMPs).

Recombinant human VEGF is lyophilized from 10mM Phosphate Potasium buffer pH 7.5 and 100 mM NaCl.

Functional studies, Cell assay, SDS-PAGE, Western Blot, Antibody Production.

2. Recombinant human VEGF 165a shows effect on kerotinocytes cell proliferation (HaCaT cells).The activity is determined by the dose-dependent stimulation of the cell proliferation 48 hours after treatment with recombinant protein. Cell viability was assessed by MTT . - It was observed 30% of cell proliferation with a concentration ?5ng/ml.

-

Centrifuge vial before opening. Lyophilized protein should be reconstituted in water to a concentration of 100 ng/ul. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. Optimal concentration should be determined for specific application and cell lines.

Room temperature